Clinical trial · no report yet · Phase 1
NCT04470024
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
- NCT04470024 ↗
- Active, not recruiting
- Providence Health & Services
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib Study of Multivalent Autophagosome Vaccine, With or Without GITR Agonist, With Sequenced Checkpoint Inhibition (Anti-PD-1) - Immunotherapy Trio in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Cancer of the Head and Neck
- Interventions
- INCAGN01876; INCMGA00012; DPV-001
- Arms
- Arm 1 · Experimental
- Arm 2 (CLOSED TO ENROLLMENT) · Experimental
- Enrollment
- 19
- Primary outcomes
- Adverse Events Assessment
- Sponsor
- Providence Health & Services
- Start
- Aug 5, 2021
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04470024 · updated Sep 3, 2026